Cargando…

HIV-1 5’-Leader Mutations in Plasma Viruses Before and After the Development of Reverse Transcriptase Inhibitor-Resistance Mutations

BACKGROUND: HIV-1 RT initiation depends on interaction between viral 5’-leader RNA, RT, and host tRNA3(Lys). We therefore sought to identify co-evolutionary changes between the 5’-leader and RT in viruses developing RT-inhibitor resistance mutations. METHODS: We sequenced 5’-leader positions 37–356...

Descripción completa

Detalles Bibliográficos
Autores principales: Nouhin, Janin, Tzou, Philip L., Rhee, Soo-Yon, Sahoo, Malaya K., Pinsky, Benjamin A., Krupkin, Miri, Puglisi, Joseph D., Puglisi, Elisabetta V., Shafer, Robert W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10274971/
https://www.ncbi.nlm.nih.gov/pubmed/37333388
http://dx.doi.org/10.1101/2023.06.04.23290942
_version_ 1785059818766073856
author Nouhin, Janin
Tzou, Philip L.
Rhee, Soo-Yon
Sahoo, Malaya K.
Pinsky, Benjamin A.
Krupkin, Miri
Puglisi, Joseph D.
Puglisi, Elisabetta V.
Shafer, Robert W.
author_facet Nouhin, Janin
Tzou, Philip L.
Rhee, Soo-Yon
Sahoo, Malaya K.
Pinsky, Benjamin A.
Krupkin, Miri
Puglisi, Joseph D.
Puglisi, Elisabetta V.
Shafer, Robert W.
author_sort Nouhin, Janin
collection PubMed
description BACKGROUND: HIV-1 RT initiation depends on interaction between viral 5’-leader RNA, RT, and host tRNA3(Lys). We therefore sought to identify co-evolutionary changes between the 5’-leader and RT in viruses developing RT-inhibitor resistance mutations. METHODS: We sequenced 5’-leader positions 37–356 of paired plasma virus samples from 29 individuals developing the NRTI-resistance mutation M184V, 19 developing an NNRTI-resistance mutation, and 32 untreated controls. 5’-leader variants were defined as positions where ≥20% of NGS reads differed from the HXB2 sequence. Emergent mutations were defined as nucleotides undergoing ≥4-fold change in proportion between baseline and follow-up. Mixtures were defined as positions containing ≥2 nucleotides each present in ≥20% of NGS reads. RESULTS: Among 80 baseline sequences, 87 positions (27.2%) contained a variant; 52 contained a mixture. Position 201 was the only position more likely to develop a mutation in the M184V (9/29 vs. 0/32; p=0.0006) or NNRTI-resistance (4/19 vs. 0/32; p=0.02; Fisher’s Exact Test) groups than the control group. Mixtures at positions 200 and 201 occurred in 45.0% and 28.8%, respectively, of baseline samples. Because of the high proportion of mixtures at these positions, we analyzed 5’-leader mixture frequencies in two additional datasets: five publications reporting 294 dideoxyterminator clonal GenBank sequences from 42 individuals and six NCBI BioProjects reporting NGS datasets from 295 individuals. These analyses demonstrated position 200 and 201 mixtures at proportions similar to those in our samples and at frequencies several times higher than at all other 5’-leader positions. CONCLUSIONS: Although we did not convincingly document co-evolutionary changes between RT and 5’-leader sequences, we identified a novel phenomenon, wherein positions 200 and 201, immediately downstream of the HIV-1 primer binding site exhibited an extraordinarily high likelihood of containing a nucleotide mixture. Possible explanations for the high mixture rates are that these positions are particularly error-prone or provide a viral fitness advantage.
format Online
Article
Text
id pubmed-10274971
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-102749712023-06-17 HIV-1 5’-Leader Mutations in Plasma Viruses Before and After the Development of Reverse Transcriptase Inhibitor-Resistance Mutations Nouhin, Janin Tzou, Philip L. Rhee, Soo-Yon Sahoo, Malaya K. Pinsky, Benjamin A. Krupkin, Miri Puglisi, Joseph D. Puglisi, Elisabetta V. Shafer, Robert W. medRxiv Article BACKGROUND: HIV-1 RT initiation depends on interaction between viral 5’-leader RNA, RT, and host tRNA3(Lys). We therefore sought to identify co-evolutionary changes between the 5’-leader and RT in viruses developing RT-inhibitor resistance mutations. METHODS: We sequenced 5’-leader positions 37–356 of paired plasma virus samples from 29 individuals developing the NRTI-resistance mutation M184V, 19 developing an NNRTI-resistance mutation, and 32 untreated controls. 5’-leader variants were defined as positions where ≥20% of NGS reads differed from the HXB2 sequence. Emergent mutations were defined as nucleotides undergoing ≥4-fold change in proportion between baseline and follow-up. Mixtures were defined as positions containing ≥2 nucleotides each present in ≥20% of NGS reads. RESULTS: Among 80 baseline sequences, 87 positions (27.2%) contained a variant; 52 contained a mixture. Position 201 was the only position more likely to develop a mutation in the M184V (9/29 vs. 0/32; p=0.0006) or NNRTI-resistance (4/19 vs. 0/32; p=0.02; Fisher’s Exact Test) groups than the control group. Mixtures at positions 200 and 201 occurred in 45.0% and 28.8%, respectively, of baseline samples. Because of the high proportion of mixtures at these positions, we analyzed 5’-leader mixture frequencies in two additional datasets: five publications reporting 294 dideoxyterminator clonal GenBank sequences from 42 individuals and six NCBI BioProjects reporting NGS datasets from 295 individuals. These analyses demonstrated position 200 and 201 mixtures at proportions similar to those in our samples and at frequencies several times higher than at all other 5’-leader positions. CONCLUSIONS: Although we did not convincingly document co-evolutionary changes between RT and 5’-leader sequences, we identified a novel phenomenon, wherein positions 200 and 201, immediately downstream of the HIV-1 primer binding site exhibited an extraordinarily high likelihood of containing a nucleotide mixture. Possible explanations for the high mixture rates are that these positions are particularly error-prone or provide a viral fitness advantage. Cold Spring Harbor Laboratory 2023-08-29 /pmc/articles/PMC10274971/ /pubmed/37333388 http://dx.doi.org/10.1101/2023.06.04.23290942 Text en https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use.
spellingShingle Article
Nouhin, Janin
Tzou, Philip L.
Rhee, Soo-Yon
Sahoo, Malaya K.
Pinsky, Benjamin A.
Krupkin, Miri
Puglisi, Joseph D.
Puglisi, Elisabetta V.
Shafer, Robert W.
HIV-1 5’-Leader Mutations in Plasma Viruses Before and After the Development of Reverse Transcriptase Inhibitor-Resistance Mutations
title HIV-1 5’-Leader Mutations in Plasma Viruses Before and After the Development of Reverse Transcriptase Inhibitor-Resistance Mutations
title_full HIV-1 5’-Leader Mutations in Plasma Viruses Before and After the Development of Reverse Transcriptase Inhibitor-Resistance Mutations
title_fullStr HIV-1 5’-Leader Mutations in Plasma Viruses Before and After the Development of Reverse Transcriptase Inhibitor-Resistance Mutations
title_full_unstemmed HIV-1 5’-Leader Mutations in Plasma Viruses Before and After the Development of Reverse Transcriptase Inhibitor-Resistance Mutations
title_short HIV-1 5’-Leader Mutations in Plasma Viruses Before and After the Development of Reverse Transcriptase Inhibitor-Resistance Mutations
title_sort hiv-1 5’-leader mutations in plasma viruses before and after the development of reverse transcriptase inhibitor-resistance mutations
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10274971/
https://www.ncbi.nlm.nih.gov/pubmed/37333388
http://dx.doi.org/10.1101/2023.06.04.23290942
work_keys_str_mv AT nouhinjanin hiv15leadermutationsinplasmavirusesbeforeandafterthedevelopmentofreversetranscriptaseinhibitorresistancemutations
AT tzouphilipl hiv15leadermutationsinplasmavirusesbeforeandafterthedevelopmentofreversetranscriptaseinhibitorresistancemutations
AT rheesooyon hiv15leadermutationsinplasmavirusesbeforeandafterthedevelopmentofreversetranscriptaseinhibitorresistancemutations
AT sahoomalayak hiv15leadermutationsinplasmavirusesbeforeandafterthedevelopmentofreversetranscriptaseinhibitorresistancemutations
AT pinskybenjamina hiv15leadermutationsinplasmavirusesbeforeandafterthedevelopmentofreversetranscriptaseinhibitorresistancemutations
AT krupkinmiri hiv15leadermutationsinplasmavirusesbeforeandafterthedevelopmentofreversetranscriptaseinhibitorresistancemutations
AT puglisijosephd hiv15leadermutationsinplasmavirusesbeforeandafterthedevelopmentofreversetranscriptaseinhibitorresistancemutations
AT puglisielisabettav hiv15leadermutationsinplasmavirusesbeforeandafterthedevelopmentofreversetranscriptaseinhibitorresistancemutations
AT shaferrobertw hiv15leadermutationsinplasmavirusesbeforeandafterthedevelopmentofreversetranscriptaseinhibitorresistancemutations